

ASX Company Announcement

End of Negotiation Period with Parvulus Suisse SA

17 January 2014

The Board of Sun Biomedical Limited (ASX: SBN or the "Company") advises that the negotiation period to acquire the business of Parvulus Suisse SA (**Parvulus**) or to licence the Intra Annular Ring technology owned by Parvulus has expired.

The Board has decided not to proceed with any further discussions with Parvulus at this moment. Sun Biomedical has been notified that Parvulus is pursuing an offer from a third party to acquire the company. Details of that offer remain in confidence.

About Sun Biomedical:

Sun Biomedical Limited is an international biotechnology company with assets in the area of occupational drug testing. The Company is commercialising new improved versions of its "Oraline[®]" hand held multi drug test device while also looking to increase its biotechnology investments. For more information on Sun Biomedical please visit <u>www.sunbiomed.com.au</u>.

Howard Digby Executive Chairman +61 434 987 750

Sun Biomedical Limited

ABN 18 001 285 230